A prospective randomized controlled trial to determine the safety and efficacy of extracorporeal shock waves therapy for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Journal Information
Full Title: Front Cardiovasc Med
Abbreviation: Front Cardiovasc Med
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Cardiac & Cardiovascular Systems
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
"The author(s) declare financial support was received for the research, authorship, and/or publication of this article.This work was supported by the Korea Medical Device Development Fund grant funded by the Korean government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (Project Number: RS-2021-KD000005)."
"Clinical Trial Registration ClinicalTrials.gov, identifier (NCT05584163)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025